IBio (NYSEMKT:IBIO) announces results from ten preclinical study arms assessing a line-up of adjuvants with IBIO-201, its proprietary lichenase carrier molecule (branded as LickM) fused to a coronavirus subunit protein, one of its two COVID-19 vaccine candidates (IBIO-200).
The data, generated on combinations delivered via intramuscular injection and intranasally, showed anti-SARS-CoV-2 spike titers 21 days after immunization which continued to increase over the 42-day study period. Distinct T cell (Th1 and Th2) responses were also observed.
Data analysis is continuing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.